22:09 , Dec 1, 2017 |  BC Week In Review  |  Financial News

Mavupharma raises 20M in series A round for STING modulators

Mavupharma Inc. (Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma is developing orally bioavailable, non-nucleotide agonists of the transmembrane protein 173 (STING; TMEM173) pathway...
23:08 , Nov 29, 2017 |  BC Extra  |  Financial News

Mavupharma raises $20M series A for STING

Mavupharma Inc. (Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma is developing orally bioavailable, non-nucleotide agonists of the transmembrane protein 173 (STING; TMEM173) pathway...
20:35 , Apr 21, 2017 |  BC Week In Review  |  Company News

Alpine, Nivalis deal

Immunology company Alpine will reverse-merge cystic fibrosis play Nivalis in a stock deal. The combined entity will retain Alpine’s name and will trade on NASDAQ under a new ticker. Alpine’s current CEO, Mitchell Gold, will...
23:24 , Apr 18, 2017 |  BC Extra  |  Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will...
07:00 , Jun 20, 2016 |  BioCentury  |  Finance

Mountain of cash

Investors in Alpine Immune Sciences Inc. decided the company's A round had to get the preclinical immunotherapy company to human efficacy data. The syndicate therefore is pouring in $48 million, about double the average size...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Financial News

Alpine Immune Sciences completes venture financing

Alpine Immune Sciences Inc., Seattle, Wash.   Business: Cancer, Autoimmune, Infectious   Date completed: 2016-06-13   Type: Venture financing   Raised: $48 million   Investors: OrbiMed Advisors; Frazier & Co.; Alpine BioVentures   ...
01:14 , Jun 14, 2016 |  BC Extra  |  Financial News

Alpine raises $48M series A round

Alpine Immune Sciences Inc. (Seattle, Wash.) raised $48 million in a series A round led by OrbiMed Advisors. Frazier Healthcare Partners and seed investor Alpine BioVentures also participated. Alpine is developing multispecific proteins to achieve...
08:00 , Feb 8, 2016 |  BioCentury  |  Emerging Company Profile

Immune orchestration

Alpine Immune Sciences Inc. is developing multispecific proteins to achieve the effects of immunotherapy combinations, but with more control and using a single molecule. The company's vIgD platform is based upon endogenous proteins that exist...
01:25 , Jul 14, 2015 |  BC Extra  |  Financial News

Financial tracks

Jay Venkatesan joined Alpine BioVentures as a managing partner. Venkatesan was EVP and general manager at Oncothyreon Inc. (NASDAQ:ONTY)....
07:00 , Sep 9, 2013 |  BioCentury  |  Finance

Banker tracks

Banker tracks Matthew McAskin joined Evercore Partnersas a senior managing director in the firm's healthcare investment banking group. McAskin was a managing director and co-head of healthcare services investment banking at Goldman Sachs. Buyside tracks Carl Harald Janson...